LBRX (LB Pharmaceuticals) Total Liabilities: $14.79 Mil (As of Mar. 2026)


LBRX LB Pharmaceuticals Inc LBRX
12 GF Score
Price $32.64
! 1 Warning Sign
View Full Analysis

What is LB Pharmaceuticals Total Liabilities?

LB Pharmaceuticals LBRX +2.26% 12 Total Liabilities is $14.79 Mil as of Mar. 2026. GuruFocus rates LBRX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

LB Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 was $14.79 Mil.

LB Pharmaceuticals's quarterly Total Liabilities increased from Sep. 2025 ($10.53 Mil) to Dec. 2025 ($11.62 Mil) and increased from Dec. 2025 ($11.62 Mil) to Mar. 2026 ($14.79 Mil).

LB Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 ($80.13 Mil) to Dec. 2024 ($128.09 Mil) but then declined from Dec. 2024 ($128.09 Mil) to Dec. 2025 ($11.62 Mil).

LB Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for LB Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

LB Pharmaceuticals Total Liabilities Chart

LB Pharmaceuticals Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
50.30 80.13 128.09 11.62

LB Pharmaceuticals Quarterly Data
Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 123.12 10.53 11.62 14.79
LBRX
12GF Score
LB Pharmaceuticals Inc LBRX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

LB Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

LB Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=7.442+(2.839+1.343
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=11.62

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=312.934-301.31
=11.62

LB Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=10.906+(2.74+1.143
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=14.79

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=393.482-378.693
=14.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $14.79 Mil mean?
LB Pharmaceuticals (LBRX) has a Total Liabilities of $14.79 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LB Pharmaceuticals and its competitors.
Is LB Pharmaceuticals' Total Liabilities too high?
LB Pharmaceuticals' current Total Liabilities is $14.79 Mil. Overall, LB Pharmaceuticals has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LB Pharmaceuticals' Total Liabilities compare to MRVI and SLDB?
LB Pharmaceuticals' Total Liabilities of $14.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for LB Pharmaceuticals and its competitors. LB Pharmaceuticals's current Total Liabilities is $14.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LB Pharmaceuticals stock overvalued right now?
LB Pharmaceuticals (LBRX) has a current Total Liabilities of $14.79 Mil. The current Total Liabilities is $14.79 Mil. LB Pharmaceuticals' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For LB Pharmaceuticals (LBRX), the current Total Liabilities is $14.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

LB Pharmaceuticals Business Description

Address One Pennsylvania Plaza, Suite 1025, New York, NY, USA, 10119
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
12GF Score

Get the complete analysis for LBRX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.64
Price